Merck shares were trading above $45 a share before the Vioxx recall late last month.
The licensing of Vioxx and its continued use in the face of unambiguous evidence of harm have been public health catastrophes.
documents show the pharmaceutical giant hid or denied evidence for years that its blockbuster arthritis drug Vioxx cause heart problems.
The Vioxx withdrawal caused Merck's third quarter profit to fall 29 percent.
The e-mail responses from Seligman and Trontell are mostly brief requests from seemingly harried bosses asking for more time to review Dr. Graham's manuscript.
We can now allude to this moment and
